Tamoxifen Therapy for Retroperitoneal Fibrosis
- Augusto Vaglio, MD;
- Paolo Greco, MD; and
- Carlo Buzio, MD
- From University of Parma, 43100 Parma, Italy.
TO THE EDITOR:
On the basis of a series of 19 patients with nonmalignant retroperitoneal fibrosis (RPF), van Bommel and colleagues (1) suggest that tamoxifen may be an effective treatment option. Their study is a relevant contribution, mostly because the use of tamoxifen therapy for RPF had previously been described only in anecdotal case reports. However, a few points warrant discussion.
The authors reported that RPF was idiopathic in 37% of their patients; in the remaining 63%, it was secondary to atherosclerosis (chronic periaortitis and perianeurysmal fibrosis) or …
This 100-word excerpt has been provided in the absence of an abstract.
Most Read
